RPL35

Across TCGA pan-cancer cohorts, RPL35 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RPL35 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RPL35 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL35 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

GBM, PDAC, and LUAD are the cancer types where RPL35 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.228	0.620	<.001	15	view →
PDAC	DFS	Tertile	IV	0.934	0.235	.024	9	view →
LUAD	DFS	Tertile	All	0.821	0.465	.018	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RPL35–GBM (DFS)

Open the GBM breakdown →